keyword
MENU ▼
Read by QxMD icon Read
search

Vaccination against HPV

keyword
https://www.readbyqxmd.com/read/29028414/immunization-attitudes-and-practices-among-family-medicine-providers
#1
Cynthia A Bonville, Joseph B Domachowske, Donald A Cibula, Manika Suryadevara
OBJECTIVE: To describe immunization attitudes and practices among family medicine providers across New York State. METHODS: In this cross-sectional survey study, family medicine providers across New York State completed a questionnaire to assess vaccine beliefs and barriers and immunization practices. STATISTICAL ANALYSIS: Descriptive statistical methods were used to define provider characteristics, knowledge and vaccine practices. RESULTS: Completed questionnaires from 226 family medicine providers were included for analysis...
October 13, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29023748/what-cervical-screening-is-appropriate-for-women-who-have-been-vaccinated-against-high-risk-hpv-a-simulation-study
#2
Rebecca Landy, Peter Windridge, Matthew S Gillman, Peter D Sasieni
Women vaccinated against HPV16/18 are approaching the age for cervical screening, however an updated screening algorithm has not been agreed. We use a microsimulation model calibrated to real published data to determine the appropriate screening intensity for vaccinated women. Natural histories in the absence of vaccination were simulated for 300,000 women using 10,000 sets of transition probabilities. Vaccination with i) 100% efficacy against HPV16/18, ii) 15% cross-protection, iii) waning vaccine efficacy, and iv) 100% efficacy against HPV16/18/31/33/45/52/58 was added, as were a range of screening scenarios appropriate to the UK...
October 11, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29017279/population-level-herd-protection-of-males-from-a-female-human-papillomavirus-vaccination-program-evidence-from-australian-serosurveillance
#3
Alexis J Pillsbury, Helen E Quinn, TaNisha D Evans, Peter B McIntyre, Julia M L Brotherton
Background: Australia instituted funded female human papillomavirus (HPV) immunization in 2007, followed by a targeted male vaccination program in 2013. To date, Australia is one of only several countries with a funded male HPV immunization program. In 2012-2013, we conducted a survey of HPV seroprevalence in males to assess whether or not a herd impact of female vaccination could be observed. Methods: We conducted a cross-sectional study of de-identified residual diagnostic test serum samples from males aged 15-39 years from laboratories in 3 Australian states and calculated the proportion seropositive to HPV types 6, 11, 16, and 18...
September 1, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28986092/population-based-hpv-vaccination-programmes-are-safe-and-effective-2017-update-and-the-impetus-for-achieving-better-global-coverage
#4
REVIEW
Julia M L Brotherton, Paul N Bloem
Persistent oncogenic human papillomavirus (HPV) is the cause of cervical cancer, as well as cancers of the anus, penis, vulva, vagina and oropharynx. There is good evidence that prophylactic HPV vaccines are immunogenic and effective against targeted-type HPV infections and type-specific genital lesions, including high-grade cervical intraepithelial neoplasia (CIN), when administered prior to HPV infection. There is good evidence that HPV vaccines are safe in population usage, with the most frequent adverse event being injection-site reactions...
September 6, 2017: Best Practice & Research. Clinical Obstetrics & Gynaecology
https://www.readbyqxmd.com/read/28984053/ten-year-immune-persistence-and-safety-of-the-hpv-16-18-as04-adjuvanted-vaccine-in-females-vaccinated-at-15-55%C3%A2-years-of-age
#5
Tino F Schwarz, Andrzej Galaj, Marek Spaczynski, Jacek Wysocki, Andreas M Kaufmann, Sylviane Poncelet, Pemmaraju V Suryakiran, Nicolas Folschweiller, Florence Thomas, Lan Lin, Frank Struyf
Women remain at risk of human papillomavirus (HPV) infection for most of their lives. The duration of protection against HPV-16/18 from prophylactic vaccination remains unknown. We investigated the 10-year immune response and long-term safety profile of the HPV-16/18 AS04-adjuvanted vaccine (AS04-HPV-16/18 vaccine) in females aged between 15 and 55 years at first vaccination. Females who received primary vaccination with three doses of AS04-HPV-16/18 vaccine in the primary phase-III study (NCT00196937) were invited to attend annual evaluations for long-term immunogenicity and safety...
October 5, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28970457/pharmacists-attitudes-and-perceived-barriers-to-human-papillomavirus-hpv-vaccination-services
#6
Tessa J Hastings, Lindsey A Hohmann, Stuart J McFarland, Benjamin S Teeter, Salisa C Westrick
Use of non-traditional settings such as community pharmacies has been suggested to increase human papillomavirus (HPV) vaccination uptake and completion rates. The objectives of this study were to explore HPV vaccination services and strategies employed by pharmacies to increase HPV vaccine uptake, pharmacists' attitudes towards the HPV vaccine, and pharmacists' perceived barriers to providing HPV vaccination services in community pharmacies. A pre-piloted mail survey was sent to 350 randomly selected community pharmacies in Alabama in 2014...
August 7, 2017: Pharmacy (Basel, Switzerland)
https://www.readbyqxmd.com/read/28968993/human-papillomavirus-16l1-58l2-chimeric-virus-like-particles-elicit-durable-neutralizing-antibody-responses-against-a-broad-spectrum-of-human-papillomavirus-types
#7
Xue Chen, Hongyang Liu, Zhirong Wang, Shuo Wang, Ting Zhang, Meili Hu, Liang Qiao, Xuemei Xu
The neutralizing antibodies elicited by human papillomavirus (HPV) major capsid protein L1 virus-like particle (VLP)-based vaccines are largely type-specific. An HPV vaccine inducing cross-neutralizing antibodies broadly will be cost-effective and of great value. To this end, we constructed HPV16L1-58L2 chimeric VLP (cVLP) by displaying HPV58 L2 aa.16-37 on the DE surface region of HPV16 L1. We found that vaccination with the HPV16L1-58L2 cVLP formulated with alum plus monophosphoryl lipid A (Alum-MPL) adjuvant elicited robust neutralizing antibodies in both mice and rabbits against all tested HPV types including HPV16/31/33/35/52/58 (genus α9), HPV18/39/45/59/68 (genus α7), HPV6/11 (genus α10), HPV2/27/57 (genus α4), and HPV5 (genus β1)...
September 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28968823/naturally-occurring-single-amino-acid-substitution-in-the-l1-major-capsid-protein-of-human-papillomavirus-type-16-alteration-of-susceptibility-to-antibody-mediated-neutralization
#8
Tingting Ning, Aaron Wolfe, Jianhui Nie, Weijin Huang, Xiaojiang S Chen, Youchun Wang
Background: Each vaccine for human papillomavirus type 16 (HPV16) has been developed on the basis of a single variant, and whether these vaccines can prevent infection due to naturally occurring variants was not clear. Methods: To examine this question, constructs of 39 naturally occurring single amino acid substitutions in L1 were generated for pseudovirion production, based on the analysis of 1204 HPV16 L1 protein sequences from the National Center for Biotechnology Information and Papilloma Virus Episteme...
September 2, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28965955/changes-in-the-prevalence-of-human-papillomavirus-following-a-national-bivalent-human-papillomavirus-vaccination-programme-in-scotland-a-7-year-cross-sectional-study
#9
Kimberley Kavanagh, Kevin G Pollock, Kate Cuschieri, Tim Palmer, Ross L Cameron, Cameron Watt, Ramya Bhatia, Catherine Moore, Heather Cubie, Margaret Cruickshank, Chris Robertson
BACKGROUND: On Sept 1, 2008, Scotland launched routine vaccination for human papillomavirus (HPV) types 16 and 18, targeted at 12-13-year-old girls, of whom 92·4% were fully vaccinated in 2008-09. In this study, we report on vaccine effectiveness of the bivalent vaccine in these vaccinated women who attended for routine cervical screening at age 20-21 years. METHODS: In this 7-year cross-sectional study (covering birth cohorts 1988-1995), we sampled approximately 1000 samples per year from those attending cervical screening at age 20-21 years and tested each for HPV...
September 28, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28950675/cervical-cancer-prevention-through-hpv-vaccination-in-low-and-middle-income-countries-in-asia
#10
Zheng Quan Toh, Paul V Licciardi, Fiona M Russell, Suzanne M Garland, Tsetsegsaikhan Batmunkh, Edward K Mulholland
Cervical cancer is ranked the first or second most common cancer in women of low- and middle-income countries (LMICs) in Asia. Cervical cancer is almost exclusively caused by human papillomavirus (HPV), and majority of the cases can be prevented with the use of HPV vaccines. The HPV vaccines have demonstrated high vaccine efficacies against HPV infection and cervical cancer precursors in clinical and post-marketing studies, and are in use in most high-income countries. However, their use in LMICs are limited mainly due to the high costs and logistics in delivering multiple doses of the vaccine...
September 27, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28939477/a-novel-candidate-ms2-phage-vlp-vaccine-displaying-a-tandem-hpv-l2-peptide-offers-similar-protection-in-mice-to-gardasil-9
#11
Lukai Zhai, Julianne Peabody, Yuk-Ying Susana Pang, John Schiller, Bryce Chackerian, Ebenezer Tumban
Human papillomaviruses (HPVs) cause approximately 5% of cancer cases worldwide. Fortunately, three prophylactic vaccines have been approved to protect against HPV infections. Gardasil-9, the most recent HPV vaccine, is predicted to offer protection against the HPV types that cause ∼90% of cervical cancer, 86% of HPV-associated penile cancers, and ∼93% of HPV-associated head & neck cancers. As an alternative to Gardasil-9, we developed and tested a novel candidate vaccine targeting conserved epitopes in the HPV minor capsid protein, L2...
September 19, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28937851/hpv-vaccine-acceptability-in-high-risk-greek-men
#12
Lea Hoefer, Savas Tsikis, George Bethimoutis, Electra Nicolaidou, Vassilios Paparizos, Christina Antoniou, Antonios Kanelleas, Leonidas Chardalias, Georgios-Emmanouil Stavropoulos, John Schneider, Angella Charnot-Katsikas
BACKGROUND: HPV is associated with malignancy in men, yet there is a lack of data on HPV knowledge, vaccine acceptability, and factors affecting vaccine acceptability in Greek men. This study aims to identify determinants of knowledge and willingness to vaccinate against HPV among high-risk Greek men. METHODS: Men (n = 298) between the ages of 18 and 55 were enrolled from the STI and HIV clinics at "Andreas Syggros" Hospital in Athens, Greece from July-October 2015...
September 22, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28927464/cervical-cancer-screening-behavior-and-associated-factors-among-women-of-ugrachandi-nala-kavre-nepal
#13
Radha Acharya Pandey, Era Karmacharya
BACKGROUND: Cervical cancer in Nepal ranks as the first most frequent cancer among women. Primary prevention measures, such as prophylactic vaccines against high risk HPV, are now available. Over time, vaccination will decrease the prevalence of the disease among younger women; however, screening will still be needed. The objective of the study was to assess the cervical cancer screening behavior and its associated factors among women of Nala Village Development Committee (VDC), Kavre...
September 19, 2017: European Journal of Medical Research
https://www.readbyqxmd.com/read/28919581/antitumor-response-to-a-codon-optimized-hpv-16-e7-hsp70-fusion-antigen-dna-vaccine
#14
Hoorieh Soleimanjahi, Hadi Razavinikoo, Fatemeh Fotouhi, Abdollah Ardebili
BACKGROUND: Vaccines based on virus-like particles are effective against Human Papilloma Virus (HPV) infection; however, they have not shown a therapeutic effect against HPV-associated diseases. New immunotherapy strategies based on immune responses against tumor antigens can positively affect the clearance of HPV-associated lesions. OBJECTIVE: To generate two therapeutic fusion DNA vaccines (optimizedE7/mouseHSP70 and wildE7/mouseHSP70) to induce antitumor specific responses in mice models...
September 2017: Iranian Journal of Immunology: IJI
https://www.readbyqxmd.com/read/28916210/modelling-multi-site-transmission-of-the-human-papillomavirus-and-its-impact-on-vaccination-effectiveness
#15
P Lemieux-Mellouki, M Drolet, M Jit, G Gingras, M Brisson
OBJECTIVE: Previous HPV models have only included genital transmission, when evidence suggests that transmission between several anatomical sites occurs. We compared model predictions of population-level HPV vaccination effectiveness against genital HPV16 infection in women, using a 1) uni-site (genital site), and a 2) multi-site model (genital and one extragenital site). METHODS: We developed a uni-site and a multi-site deterministic HPV transmission model, assuming natural immunity was either site-specific or systemic...
August 25, 2017: Epidemics
https://www.readbyqxmd.com/read/28912369/customized-viral-immunotherapy-for-hpv-associated-cancer
#16
Matthew J Atherton, Kyle B Stephenson, Jonathan Pol, Fuan Wang, Charles Lefebvre, David F Stojdl, Jake K Nikota, Anna Dvorkin-Gheva, Andrew Nguyen, Lan Chen, Stephanie Johnson-Obaseki, Patrick J Villeneuve, Jean-Simon Diallo, Jim Dimitroulakos, Yonghong Wan, Brian D Lichty
The viral-transforming proteins E6 and E7 make human papillomavirus-positive (HPV(+)) malignancies an attractive target for cancer immunotherapy. However, therapeutic vaccination exerts limited efficacy in the setting of advanced disease. We designed a strategy to induce substantial specific immune responses against multiple epitopes of E6 and E7 proteins based on an attenuated transgene from HPV serotypes 16 and 18 that is incorporated into MG1-Maraba virotherapy (MG1-E6E7). Mutations introduced to the transgene abrogate the ability of E6 and E7 to perturb p53 and retinoblastoma, respectively, while maintaining the ability to invoke tumor-specific, multifunctional CD8(+) T-cell responses...
October 2017: Cancer Immunology Research
https://www.readbyqxmd.com/read/28887001/major-findings-and-recent-advances-in-virus-like-particle-vlp-based-vaccines
#17
REVIEW
Mona O Mohsen, Lisha Zha, Gustavo Cabral-Miranda, Martin F Bachmann
Virus-like particles (VLPs) have made giant strides in the field of vaccinology over the last three decades. VLPs constitute versatile tools in vaccine development due to their favourable immunological characteristics such as their size, repetitive surface geometry, ability to induce both innate and adaptive immune responses as well as being safe templates with favourable economics. Several VLP-based vaccines are commercially available including vaccines against Human Papilloma Virus (HPV) such as Cervarix(®), Gardasil(®) & Gardasil9(®) and Hepatitis B Virus (HBV) including the 3rd generation Sci-B-Vac™...
September 5, 2017: Seminars in Immunology
https://www.readbyqxmd.com/read/28886907/final-efficacy-immunogenicity-and-safety-analyses-of-a-nine-valent-human-papillomavirus-vaccine-in-women-aged-16-26-years-a-randomised-double-blind-trial
#18
Warner K Huh, Elmar A Joura, Anna R Giuliano, Ole-Erik Iversen, Rosires Pereira de Andrade, Kevin A Ault, Deborah Bartholomew, Ramon M Cestero, Edison N Fedrizzi, Angelica L Hirschberg, Marie-Hélène Mayrand, Angela Maria Ruiz-Sternberg, Jack T Stapleton, Dorothy J Wiley, Alex Ferenczy, Robert Kurman, Brigitte M Ronnett, Mark H Stoler, Jack Cuzick, Suzanne M Garland, Susanne K Kjaer, Oliver M Bautista, Richard Haupt, Erin Moeller, Michael Ritter, Christine C Roberts, Christine Shields, Alain Luxembourg
BACKGROUND: Primary analyses of a study in young women aged 16-26 years showed efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) vaccine against infections and disease related to HPV 31, 33, 45, 52, and 58, and non-inferior HPV 6, 11, 16, and 18 antibody responses when compared with quadrivalent HPV (qHPV; HPV 6, 11, 16, and 18) vaccine. We aimed to report efficacy of the 9vHPV vaccine for up to 6 years following first administration and antibody responses over 5 years...
September 5, 2017: Lancet
https://www.readbyqxmd.com/read/28884278/hpv-prevalence-in-vulvar-cancer-in-austria
#19
Sophie Pils, Lisa Gensthaler, Laia Alemany, Reinhard Horvat, Silvia de Sanjosé, Elmar A Joura
BACKGROUND: Even if vulvar cancer is not common, over one hundred women are affected in Austria per year. There is strong evidence that basaloid and warty variants are associated with types of human papillomavirus (HPV). METHODS: The aim of this study is to analyze the types of HPV in vulvar cancer in Austria. This cross-sectional period-prevalence international collaborative study on archival specimens was performed in cooperation with the Institut Catalan di Oncologia in Barcelona, Spain...
September 7, 2017: Wiener Klinische Wochenschrift
https://www.readbyqxmd.com/read/28881394/the-effect-of-vaccination-against-human-papillomavirus-on-fecundability
#20
Kathryn A McInerney, Elizabeth E Hatch, Amelia K Wesselink, Ellen M Mikkelsen, Kenneth J Rothman, Rebecca B Perkins, Lauren A Wise
BACKGROUND: The human papillomavirus (HPV) vaccine was developed to prevent infection with strains of HPV that cause cervical cancer. While HPV infection has been associated with reduced semen quality and lower pregnancy rates in some studies, no studies have examined the relationship between HPV vaccination and fecundability. We hypothesize that HPV prevention via vaccination will protect fecundity. METHODS: We analysed data from Pregnancy Study Online (PRESTO), a preconception cohort of North American pregnancy planners...
September 7, 2017: Paediatric and Perinatal Epidemiology
keyword
keyword
38921
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"